At the start of the month, food delivery service DoorDash announced it raised another $535 million in Series D funding. The company is looking to expand their reach and employee numbers with these funds. Tony Xu is the CEO of DoorDash. He joins Cheddar to explain some of their goals with this new round. DoorDash is looking to grow their employee base from 550 to 800 employees over this next year. The growth will mostly be in engineering and sales. Xu also says DoorDash is expected to spread from 600 cities to around 1600 cities across North America this year as well. Another focus for DoorDash will be building a strong platform for "last mile logistics." When asked what advice Xu instills on his employees, the CEO says he tells them to keep focused on the smallest level of details. In his opinion, that is what's gotten the company to where it is today.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More